

Global Anorexiant Market Size study, by Route of Administration (Subcutaneous Anorexiant, Oral Anorexiant), by Distribution Channel and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G8E8B7D6BB83EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G8E8B7D6BB83EN

Abstracts

Global Anorexiants Market is valued approximately at USD 0.9 billion in 2023 and is anticipated to grow with a steady growth rate of more than 4.77% over the forecast period 2024-2032. Anorexiants, widely recognized as appetite suppressants, are pharmacological agents used to manage obesity by influencing the central nervous system to curb appetite. In an era where the rising tide of obesity continues to burden global healthcare systems, anorexiants are increasingly becoming an essential tool in combating chronic weight-related conditions. The market's momentum is being spurred by an uptick in sedentary lifestyles, rising incidences of lifestyle disorders such as type 2 diabetes and hypertension, and a strong demand for effective pharmacological weight management options. This growing demand has paved the way for continuous innovation in delivery formats and molecular formulations, aiming to enhance efficacy and minimize adverse effects.

Fueled by rapid urbanization and escalating health consciousness, the anorexiants market is experiencing a significant transformation driven by both consumer and clinical interests. Pharmaceutical giants are leveraging advanced biotechnology platforms to craft targeted anorexiants that offer prolonged satiety and improved metabolic regulation. Furthermore, regulatory agencies in major economies have begun to streamline approval pathways for novel anti-obesity drugs, encouraging pharmaceutical investments and accelerating the pipeline. At the same time, ongoing clinical trials and promising results from combination therapies are contributing to the credibility of anorexiants as a sustainable long-term strategy in weight control. Nevertheless, the market's growth trajectory faces headwinds from safety concerns, particularly around

the potential for cardiovascular side effects and dependency risks. These factors have led to rigorous post-marketing surveillance and restricted prescriptions in some regions.

Despite these challenges, industry players are exploring strategic alliances and co-marketing agreements to tap into underserved regions where obesity is emerging as a public health crisis. North America leads the market in terms of product innovation, driven by an established pharmaceutical landscape and high consumer acceptance of prescription weight-loss medications. Government initiatives such as insurance coverage for obesity-related treatments and public awareness campaigns further catalyze the market. Simultaneously, the Asia Pacific region is poised to witness the highest CAGR, buoyed by expanding healthcare access, urban dietary patterns, and growing middle-class populations. With obesity on the rise and social stigma diminishing, more patients are actively seeking medically supervised weight loss solutions, thereby increasing prescription volumes.

Europe continues to be a strategic hub for clinical research and drug development, backed by robust regulatory frameworks and collaborative R&D infrastructure. In Germany and the UK, healthcare systems are increasingly integrating obesity treatment into primary care services. Meanwhile, Latin America and the Middle East & Africa are gradually emerging as lucrative frontiers due to increasing obesity rates, growing awareness about lifestyle disorders, and improving access to therapeutics. Although affordability remains a concern in these regions, local production and generic competition are expected to make anorexiant more accessible in the near future. As the global obesity epidemic intensifies, the market for anorexiants stands at the forefront of a health revolution, blending scientific innovation with public health urgency.

Major market player included in this report are:

Novo Nordisk

Pfizer

Eli Lilly and Company

Amgen Inc.

Johnson & Johnson

Arena Pharmaceuticals

Takeda Pharmaceutical Company Ltd.

Boehringer Ingelheim

Rhythm Pharmaceuticals

Gelesis Inc.

Curax Pharmaceuticals LLC

GlaxoSmithKline plc

AstraZeneca

Bayer AG

Teva Pharmaceutical Industries Ltd.

The detailed segments and sub-segment of the market are explained below:

By Route of Administration

Subcutaneous Anorexiant

Oral Anorexiant

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market

approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL ANOREXIANTS MARKET EXECUTIVE SUMMARY

- 1.1. Global Anorexiant Market Size & Forecast (2022 – 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Route of Administration
 - 1.3.2. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL ANOREXIANTS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Patient Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Health & Safety Considerations
 - 2.3.4.4. Patient Awareness & Adoption
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
 - Historical year – 2022
 - Base year – 2023
 - Forecast period – 2024 to 2032
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL ANOREXIANTS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of Obesity and Overweight Individuals
- 3.1.2. Growing Demand for Pharmacotherapeutic Weight-Loss Solutions
- 3.1.3. Surging Investment in Obesity-Related R&D

3.2. Market Challenges

- 3.2.1. Safety Concerns and Regulatory Hurdles
- 3.2.2. High Cost of Novel Anorexiant Therapies
- 3.2.3. Reimbursement and Access Constraints

3.3. Market Opportunities

- 3.3.1. Development of Long-Acting and Combination Formulations
- 3.3.2. Expansion into Emerging and Untapped Markets
- 3.3.3. Digital Health Integration for Patient Adherence

CHAPTER 4. GLOBAL ANOREXIANTS MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Five Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL ANOREXIANTS MARKET SIZE & FORECASTS BY ROUTE

Global Anorexiants Market Size study, by Route of Administration (Subcutaneous Anorexiants, Oral Anorexiants),...

OF ADMINISTRATION 2022 – 2032

5.1. Segment Dashboard

5.2. Global Anorexiant Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million)

5.2.1. Subcutaneous Anorexiant

5.2.2. Oral Anorexiant

CHAPTER 6. GLOBAL ANOREXIANTS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL 2022 – 2032

6.1. Segment Dashboard

6.2. Global Anorexiant Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)

CHAPTER 7. GLOBAL ANOREXIANTS MARKET SIZE & FORECASTS BY REGION 2022 – 2032

7.1. North America Anorexiant Market

7.1.1. U.S. Anorexiant Market

7.1.1.1. Route of Administration breakdown size & forecasts, 2022 – 2032

7.1.1.2. Distribution Channel breakdown size & forecasts, 2022 – 2032

7.1.2. Canada Anorexiant Market

7.2. Europe Anorexiant Market

7.2.1. U.K. Anorexiant Market

7.2.2. Germany Anorexiant Market

7.2.3. France Anorexiant Market

7.2.4. Spain Anorexiant Market

7.2.5. Italy Anorexiant Market

7.2.6. Rest of Europe Anorexiant Market

7.3. Asia-Pacific Anorexiant Market

7.3.1. China Anorexiant Market

7.3.2. India Anorexiant Market

7.3.3. Japan Anorexiant Market

7.3.4. Australia Anorexiant Market

7.3.5. South Korea Anorexiant Market

7.3.6. Rest of Asia-Pacific Anorexiant Market

7.4. Latin America Anorexiant Market

7.4.1. Brazil Anorexiant Market

- 7.4.2. Mexico Anorexiant Market
- 7.4.3. Rest of Latin America Anorexiant Market
- 7.5. Middle East & Africa Anorexiant Market
 - 7.5.1. Saudi Arabia Anorexiant Market
 - 7.5.2. South Africa Anorexiant Market
 - 7.5.3. Rest of Middle East & Africa Anorexiant Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Novo Nordisk
 - 8.1.2. Pfizer
 - 8.1.3. Eli Lilly
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Novo Nordisk
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. Pfizer
 - 8.3.3. Eli Lilly
 - 8.3.4. Amgen
 - 8.3.5. Arena Pharmaceuticals
 - 8.3.6. Johnson & Johnson
 - 8.3.7. Boehringer Ingelheim
 - 8.3.8. Takeda

CHAPTER 9. RESEARCH PROCESS

- 9.1. Research Process
 - 9.1.1. Data Mining
 - 9.1.2. Analysis
 - 9.1.3. Market Estimation
 - 9.1.4. Validation
 - 9.1.5. Publishing
- 9.2. Research Attributes

I would like to order

Product name: Global Anorexiants Market Size study, by Route of Administration (Subcutaneous Anorexiants, Oral Anorexiants), by Distribution Channel and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G8E8B7D6BB83EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8E8B7D6BB83EN.html>